Tag: biopsy

Unnecessary treatment. Morbidities (side effects). Up to 67% overdiagnosis. These words and phrases come from a published literature review that asks, “What chance do we have to decrease prostate cancer overdiagnosis and overtreatment?” For many, the answer lies in... keep reading

Who doesn’t love to save millions of dollars? Multiparametric MRI offers huge savings in healthcare spending by ruling out need for a prostate biopsy—not to mention saving thousands of men the anxiety of being rushed into something unpleasant that may be totally unnecessary. keep reading

It’s a fact. America’s population is aging. Lifespans are increasing due to medical and lifestyle advances, so a healthy 70-year old man’s life expectancy may be greater than his father’s was at the same age. Here’s another fact: prostate cancer (PCa), the most common tumor cancer in men, is considered a disease of aging. The keep reading

Prostate cancer (PCa) is the most common non-skin cancer in men, and it’s one of the most curable if it’s detected early. In addition, the American Cancer Society points out, “Catching cancer early often allows for more treatment options.” This is definitely true for PCa, since the number of available treatment methods has grown in keep reading

There’s a time and a place for discussion before making a decision, but a doctor’s visit prior to a PSA blood draw is not the time or the place. The current recommendation is as follows: The U.S. Preventive Services Task Force (USPSTF) recommends that men ages 55 to 69 years discuss the possible benefits and keep reading

Did you know there are different types of prostate cancer (PCa)? That’s because cancer starts when the genes in a healthy cell mutate, causing it to behave abnormally. Since the structure of the prostate gland is composed of distinct types of cells, the kind of PCa is determined by the kind of cell from which keep reading

What’s more important: saving men’s lives or saving healthcare dollars? Obviously, saving life is the top priority. But, if the two values could be combined at a single stroke, who wouldn’t jump at it? The way to achieve this integration is spelled out in a Nov. 2022 online JAMA Oncology article. In “Cost effectiveness of keep reading

As far as we know, no one has yet come up with a better mousetrap. This is also true of screening tests for prostate cancer (PCa). As everyone knows, the current PSA (prostate specific antigen) blood test is not specific for PCa. It only registers increased activity/irritation of the gland. Yes, it could mean cancer, keep reading

Let’s say a real estate investor buys a dilapidated house, intending to tear it down and develop the property with a larger, up-to-date home. Since the house will be demolished, the investor decides to skip going through the rooms for an on-site inspection. If any furnishings were left behind, when the bulldozers come to do keep reading

“…any energy source can be applied to the super-active surveillance concept allowing more men to consider a tissue-preserving therapy for prostate cancer.” – Corradi et al. 2019[i] Thanks to a growing recognition among professionals that clinically insignificant PCa may never become life-threatening, a larger percentage of low-risk PCa patients are starting their treatment journey with keep reading